Home / Themes / MedTech Long '25: Diagnostic Platforms
MedTech Long '25: Diagnostic Platforms
Last updated
Theme thesis · 2/5 sections · Tickers 0 with notes · 7 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsAI-enhanced sequencing and immunodiagnostic platforms are crossing cost-and-throughput tipping points just as U.S. reimbursement expands to blood-based Alzheime
Thesis
AI-enhanced sequencing and immunodiagnostic platforms are crossing cost-and-throughput tipping points just as U.S. reimbursement expands to blood-based Alzheimer's, multi-cancer and AI-radiology codes. PacBio's Revio and Illumina's NovaSeq X upgrades slash $/Gb, Quanterix's p-Tau217 wins early CMS support, and iCAD's ProFound AI Risk gains CPT traction, anchoring a demand rebound for high-complexity centralized labs despite past funding droughts.
Bull case
Platform refresh cycle: PacBio Revio & Illumina NovaSeq X shipments up >40 % Y/Y; labs upgrading for long-read & multi-omic throughput.
Reimbursement catalysts: draft CLFS adds Quanterix p-Tau217; AMA issues new AI-breast-risk CPT codes boosting iCAD pipeline.
Consolidation premium: Quanterix–Akoya deal and rising M&A multiples signal strategic value of specialized assay content.
Bear case
Capital budget crunch: NIH and hospital austerity freeze new sequencer/assay purchases despite tech gains.
Regulatory drag: FDA's proposed LDT rule revives costly premarket reviews, delaying novel tests.
Reimbursement gap: CMS delays national coverage for AD blood tests; payors balk at AI add-on fees, capping volume growth.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Claims volume for new AI breast-risk CPT/HCPCS codes (e.g., X409T) | Monthly | Payer uptake of AI diagnostics; rising claim counts validate iCAD & ICAD partners' revenue ramp | Google_Sheets |
| Revio & NovaSeq X cumulative flow-cell shipments | Quarterly | Real-time adoption of next-gen long- and short-read platforms driving MASS & PACB consumables revenue | Google_Sheets |
| CMS Clinical Lab Fee Schedule rate for p-Tau 217 & multi-marker AD tests | Proposed July, Final November annually | Reimbursement hurdle for Quanterix and EXAS neuro panels; upward revisions unlock test volumes | Google_Sheets |
Constituents
- ICADT3· no notes yet
- ILMNT3· no notes yet
- MASST3· no notes yet
- PACBT3· no notes yet
- PSNLT3· no notes yet
- QDELT3· no notes yet
- QTRXT3· no notes yet